Today: 21 May 2026
Browse Category

NASDAQ:WRBY 30 December 2025 - 19 May 2026

Warby Parker Shares Slip After AI Glasses Reveal; Investors React

Warby Parker Shares Slip After AI Glasses Reveal; Investors React

Warby Parker shares fell Tuesday after the company unveiled its first “Intelligent Eyewear” with Google and Samsung, but did not disclose pricing or a launch date. The stock traded at $25.51, with volume triple the average. The new AI-powered glasses are set for a fall launch and will support multiple prescriptions and lens options. First-quarter revenue rose 8.3% to $242.4 million, while gross margin slipped to 54%.
19 May 2026
···
Warby Parker stock slips in premarket after 18% surge on buyback, 2026 outlook

Warby Parker stock slips in premarket after 18% surge on buyback, 2026 outlook

Warby Parker shares fell 2.3% to $25.05 in premarket trading Friday after a 17.8% rally the prior day. The company reported its first full-year profit, announced a $100 million share buyback, and raised 2026 revenue and EBITDA targets. Piper Sandler cited weather as a drag on early-quarter demand but reiterated an Overweight rating. Warby Parker plans to open 50 new stores and warned of tariff and shipping cost risks.
27 February 2026
·
Warby Parker stock price today: WRBY falls nearly 4% in thin year-end trading

Warby Parker stock price today: WRBY falls nearly 4% in thin year-end trading

Warby Parker shares fell 3.9% to $22.11 in early afternoon trading Tuesday, underperforming the broader market amid thin year-end volumes. Nearly 3 million shares changed hands as investors awaited Federal Reserve meeting minutes. The company’s recent AI glasses partnership with Google has drawn attention, but traders remain focused on near-term fundamentals. Retail stocks were mixed, with National Vision down 1.7%.
30 December 2025
·

Stock Market Today

  • Pyramid Technoplast Earnings Masked by Weak Free Cash Flow, Raising Investor Concerns
    May 20, 2026, 9:18 PM EDT. Pyramid Technoplast Limited (NSE:PYRAMID) reported a profit of ₹288.2 million for the year ending March 2026, yet the company posted negative free cash flow (FCF) of ₹1.2 billion, revealing an accrual ratio of 0.39. This ratio, which measures the difference between accounting profit and cash profit, suggests earnings may not be supported by cash generation, a potential warning sign for investors. A high positive accrual ratio may indicate paper profits rather than real cash profits, often linked to lower future earnings. Despite 9.4% earnings per share growth, the sustained negative FCF raises concerns about the quality and sustainability of Pyramid's profits. Investors should also assess balance sheet strength and be cautious about possible underlying risks affecting long-term profitability.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop